文献速递乳腺癌放疗姑息放疗与转移瘤

真实世界中阿贝西利与放疗同步用于HR+/HER2-转移性乳腺癌的使用与安全性

Utilization and Safety of Concurrent Use of Abemaciclib and Radiation Therapy Among Patients With HR+, HER2- Metastatic Breast Cancer in the Real-World Setting.
PubMed 文献 · Adv Radiat Oncol · 2025-12-31

该回顾性研究基于美国Flatiron Health电子健康记录数据库,纳入174例HR+/HER2-转移性乳腺癌女性患者,描述阿贝西利与放疗同步使用的真实世界模式与安全性。同步期间76.4%患者阿贝西利剂量未调整,常见真实世界不良事件为腹泻(73.0%)、乏力(62.6%)、皮疹(27.6%)和中性粒细胞减少(23.0%),中位至治疗终止时间为368天(95%CI 290-516)。

要点

  • 同步放疗与阿贝西利期间,76.4%患者阿贝西利剂量未调整,仅4.0%停药。
  • 同步期间最常见真实世界不良事件为腹泻73.0%、乏力62.6%。
  • 中位至治疗终止时间为368天(95%CI 290-516)。

核心结论

  • 多数患者同步放疗与阿贝西利时无需调整或中断阿贝西利剂量,提示该联合方案在HR+/HER2-转移性乳腺癌中耐受性良好。

研究设计与样本

  • 回顾性研究,数据来自美国Flatiron Health全国去标识电子健康记录纵向数据库,索引日期为阿贝西利起始日期(2017年9月至2021年9月),同步放疗定义为任何放疗与阿贝西利治疗至少重叠1天,最短随访90天。
  • 共纳入174例女性HR+/HER2-转移性乳腺癌患者,中位随访17.5个月(IQR 10.1-26.5),中位年龄63.0岁(IQR 54.0-71.0)。

主要发现

  • 索引时8.0%患者ECOG体能状态≥2,31.0%患者为转移性乳腺癌;阿贝西利使用前20.1%接受过化疗、28.2%接受过其他CDK4/6抑制剂。
  • 47.7%患者阿贝西利联合氟维司群,76.4%患者阿贝西利起始剂量为150 mg每日两次;86.8%患者在阿贝西利起始时或之后开始放疗。
  • 同步放疗与阿贝西利期间,76.4%患者阿贝西利剂量无变化,16.7%暂停用药、2.3%减量、4.0%停药;真实世界不良事件发生率为腹泻73.0%、乏力62.6%、皮疹27.6%、中性粒细胞减少23.0%。
  • 中位至治疗终止时间为368天(95%CI 290-516)。

临床怎么用

  • 对于HR+/HER2-转移性乳腺癌患者,同步放疗与阿贝西利时多数无需调整阿贝西利剂量,但需关注腹泻、乏力、皮疹和中性粒细胞减少等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Real-world data on tolerability of concurrent radiation therapy (RT) and abemaciclib are limited. This study described real-world utilization and safety of concurrent RT and abemaciclib in patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). METHODS AND MATERIALS: This retrospective study accessed data from the Flatiron Health United States nationwide deidentified electronic health records-derived longitudinal database. Abemaciclib initiation date was the index date (September 2017-September 2021). Concurrent RT was defined as receipt of any RT with ≥1 day of overlap with abemaciclib therapy. The minimum follow-up time was 90 days. Patient characteristics, treatment patterns, and real-world adverse events (rwAEs) were presented descriptively; Kaplan-Meier methods were used to assess time to treatment discontinuation. RESULTS: This study included 174 female patients with a median follow-up time of 17.5 (IQR, 10.1-26.5) months. The median age was 63.0 (IQR, 54.0-71.0) years, 8.0% had Eastern Cooperative Oncology Group Performance Status ≥ 2 at index and 31.0% had MBC. Prior to abemaciclib use, 20.1% and 28.2% of patients had chemotherapy or other CDK4/6 inhibitors, respectively. About half of the patients (47.7%) received abemaciclib in combination with fulvestrant, and 76.4% initiated abemaciclib at 150 mg twice daily. Overall, 151 patients (86.8%) initiated RT at or after initiation of abemaciclib. During concurrent RT and abemaciclib use, 76.4% of patients had no dose change in abemaciclib; 16.7% and 2.3% had a dose hold or dose reduction, respectively; 4.0% discontinued abemaciclib. The incidence of rwAEs during concurrent abemaciclib + RT were diarrhea (73.0%), fatigue (62.6%), rash (27.6%), and neutropenia (23.0%). The median (95% CI) time to treatment discontinuation was 368 (290-516) days. CONCLUSIONS: Most patients did not require a dose modification or interruption with concurrent RT and abemaciclib. These findings suggest that the addition of RT to abemaciclib therapy is well tolerated in patients with HR+, HER2- MBC.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Gathirua-Mwangi W, Kim S, Martin H, et al. Utilization and Safety of Concurrent Use of Abemaciclib and Radiation Therapy Among Patients With HR+, HER2- Metastatic Breast Cancer in the Real-World Setting. Adv Radiat Oncol. 2025. PMID: 41732736. doi:10.1016/j.adro.2025.101992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。